Tocofersolan
| 證據等級: L5 | 預測適應症: 2 個 |
目錄
Tocofersolan: From Unknown Original Indication to Amenorrhea
One-Sentence Summary
Tocofersolan (a water-soluble vitamin E / TPGS formulation) currently has no documented original indication or mechanism-of-action data in this evidence pack. The TxGNN model predicts it may be effective for Amenorrhea, but this prediction is currently supported by 0 clinical trials and 0 publications — model output only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | No data available |
| Predicted New Indication | Amenorrhea |
| TxGNN Prediction Score | 99.31% |
| Evidence Level | L5 |
| Germany Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data for Tocofersolan is not available, and no original indication is documented in this evidence pack. Based on general pharmacological knowledge, Tocofersolan is a water-soluble esterified form of vitamin E (TPGS), typically used to support vitamin E absorption/supplementation in conditions of fat malabsorption — but this is not confirmed by the current dataset and should not be treated as established fact.
For the top predicted indication (Amenorrhea), the model-generated rationale notes: "No known mechanism directly links vitamin E/TPGS to menstrual disorders or amenorrhea. The high TxGNN score likely reflects indirect associations between vitamin E and endocrine/reproductive nodes within the knowledge graph, rather than a validated biological pathway." This mechanistic link is therefore speculative and not supported by direct evidence.
Given the absence of MOA data, original indication data, and any supporting clinical trials or literature, this prediction should be treated as a hypothesis generated purely from graph-based inference, not as a mechanistically or clinically substantiated repurposing candidate.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Germany Market Information
Tocofersolan is currently not marketed in Germany, and no authorization records are available in this evidence pack.
Safety Considerations
Please refer to the package insert for safety information.
Note: A blocking data gap has been identified — TFDA/BfArM label warnings and contraindications are not yet available, which prevents this candidate from entering the S1 safety pre-assessment stage.
Conclusion and Next Steps
Decision: Hold
Rationale: This candidate is supported only by a TxGNN model score (L5 evidence) with no clinical trials, no literature, no confirmed mechanism of action, and no market presence. A blocking data gap on drug label warnings/contraindications also prevents any safety pre-assessment.
To proceed, the following is needed:
- TFDA/BfArM package insert data (warnings, contraindications) — required to clear the blocking data gap
- Confirmed mechanism of action (MOA) from DrugBank or primary literature
- Confirmed original indication(s) for the drug
- Any preclinical, observational, or clinical evidence specifically linking Tocofersolan to amenorrhea or reproductive/endocrine pathways
- Reassessment of the secondary prediction (Acne), which is similarly unsupported (L5, 0 trials, 0 literature)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.